Physician profile
David D Kim
NPI 1508805052
$4,340.06
in general payments reported to CMS, 2019-2025
23 companies · $222 in 2025
The $222 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,059 · 2020: $450 · 2021: $535 · 2022: $689 · 2023: $441 · 2024: $945 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,593 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,592.82 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $675.84 | 2019-2022 | |
| Abbvie INC. | $675.48 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $577.64 | 2019-2021 | |
| Alcon Vision LLC | $557.02 | 2022-2025 | Rocklatan, Constellation, Hydrus Microstent |
| Johnson & Johnson Surgical Vision, INC. | $312.93 | 2022-2024 | Catalys System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $218.58 | 2019-2021 | |
| New World Medical,INC. | $179.61 | 2019-2025 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Shire North American Group INC | $165.92 | 2019 | |
| Glaukos Corporation | $153.29 | 2022-2024 | |
| Sight Sciences, INC. | $145.04 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $139.00 | 2022-2024 | Vyzulta, Scoutpro Osmolarity System |
| Kala Pharmaceuticals, INC. | $125.62 | 2019-2020 | |
| Biotissue Holdings INC. | $98.07 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $80.96 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $57.85 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $37.73 | 2022-2024 | Iyuzeh |
| Rayner Intraocular Lenses Limited | $34.42 | 2025 | Omidria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.22 | 2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $20.48 | 2019 | |
| Currax Pharmaceuticals LLC | $17.17 | 2024 | Contrave |
| Oyster Point Pharma, INC. | $16.45 | 2024 | Tyrvaya |
| Ocular Therapeutix, INC. | $14.23 | 2020 | |
| Harrow Eye, LLC | $13.51 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.